A second API supplier, a wider drying temperature range: sooner or later an approved product needs a change to what its dossier says.
ICH Q12, adopted in November 2019, is the guideline written for that phase of a product's life. It lists eight tools and enablers. Three of them are the ones a plant meets first.
Established conditions (ECs) are the elements of the dossier considered necessary to assure product quality. Q12 defines them as legally binding, and any change to one necessitates a submission to the regulatory authority. For a plant this is the tool with daily use: where a dossier states which elements are ECs, site change control can sort a proposed change by looking it up instead of by debate. Q12 does not make identifying them mandatory, so not every dossier will.
The second tool, a post-approval change management protocol (PACMP), is agreed before the change is made: the company describes the change, the studies and the acceptance criteria, and the authority approves the protocol in advance. The third, the product lifecycle management (PLCM) document, is the central repository for the ECs and their reporting categories.
Q12 says an effective pharmaceutical quality system, as described in ICH Q10, is necessary to support use of these tools, and that the flexibility on offer is subject to the regulatory framework in place.
Topics
Industries




